Safety and Efficacy of Nanofiltered C1 Esterase Inhibitor (Human) (C1 INH-nf) for the Treatment of Laryngeal Attacks in Subjects with Hereditary Angioedema
The United States Hereditary Angioedema
Association (HAEA) is a not-for profit organization that represents approximately 2,300 HAE families.
ViroPharma commercializes Cinryze (C1 esterase inhibitor [human]) for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema
Cinryze is a C1 inhibitor replacement therapy that treats the underlying cause of hereditary angioedema
(HAE) - a deficiency of the C1 inhibitor plasma protein that mediates swelling.
HAE is an especially challenging disease for patients to manage, said Anthony Castaldo, President of the Hereditary Angioedema
Association (US HAEA), a non-profit patient services and research organization with a membership of over 5,000 HAE patients in the United States.
Sponsoring of an HAE symposium at the Second Latin-American Congress on Hereditary Angioedema
in Veracruz, Mexico
ViroPharma Incorporated (NASDAQ: VPHM), today announced its support of the second annual international Hereditary Angioedema
DX-2930 may be a viable prophylactic treatment option for hereditary angioedema
and other plasma kallikrein-mediated (PKM) diseases.
The drug, dubbed Cinryze, is the only drug in Europe with the indication for the prevention of hereditary angioedema
and was introduced on the US market several years ago, news agency Europa Press quoted the director of the Spanish unit of ViroPharma, Gilbert Credi, as saying today.
SeeNews) - Nov 7, 2012 - Dutch biotechnology firm Pharming Group NV (AMS:PHARM) and US Santarus Inc (NASDAQ:SNTS) unveiled today promising top-line Phase III data for Ruconest (recombinant human C1 esterase inhibitor) in acute hereditary angioedema
Recent laboratory research into the pathophysiology of hereditary angioedema
(HAE) has identified bradykinin as a crucial vasoactive compound in the pathophysiology of attacks (3).
(HAE) is a relatively rare, potentially life-threatening condition caused by a genetic (autosomal dominant) deficiency of C 1 esterase inhibitor (C1-INH), a human plasma protein that regulates the contact (bradykinin-forming), complement, and fibrinolytic systems.
Chagas Kde N, Arruk VG, Andrade ME et al: Therapeutic approach of hereditary angioedema
Angioedema in a patient with positive family history and low C4 is characteristic of hereditary angioedema
SAN DIEGO -- Patients with hereditary angioedema
wait 15 years on average between the onset of symptoms and diagnosis, according to a poster that was presented at the annual meeting of the American Association for Allergy, Asthma, and Immunology.